Orthologic amends PMA (pre-market approval) for spinal fusion product:
This article was originally published in Clinica
Executive Summary
OrthoLogic has submitted its amended premarket approval (PMA) supplement for its spinal fusion product, the SpinaLogic-1000. This is the second amendment made by the Tempe, Arizona-based company since the original supplement was submitted to the FDA in August last year (see Clinica No 823, p 17). SpinaLogic-1000, which uses OrthoLogic's combined magnetic field technology, is designed to act as an adjunct to spinal fusion surgery and to help stimulate bone fusion.